Company news
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) news
Every Lineage Cell Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
May 5, 2026
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
May 4, 2026
Lineage Announces Formation of Scientific Advisory Board
April 13, 2026
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
March 24, 2026
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 5, 2026
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
February 26, 2026
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 6, 2026
Lineage Cell Therapeutics Issues Letter to Stockholders
January 5, 2026
Lineage Cell Therapeutics : Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech
November 24, 2025
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
October 30, 2025
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
September 8, 2025
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
September 2, 2025
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
August 26, 2025
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
August 5, 2025
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
August 4, 2025
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
June 23, 2025
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
June 5, 2025
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 14, 2025
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
May 12, 2025
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
May 1, 2025
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
April 22, 2025